Therefore, when ARNI is used in combination with hypoglycemic drugs, we suggest closely monitoring blood glucose and appropriately reducing the dose of insulin secretagogue or insulin in patients with a high risk of hypoglycemia to reduce this risk. The gene discussed is INS; the disease is Hypoglycemia.